Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings

Core Insights - Haemonetics reported revenue of $330.6 million for the quarter ended March 2025, a decrease of 3.7% year-over-year, but exceeded the Zacks Consensus Estimate by 1.00% [1] - The company's EPS for the quarter was $1.24, up from $0.90 in the same quarter last year, representing a surprise of 1.64% over the consensus estimate of $1.22 [1] Revenue Breakdown - Plasma segment net revenues were $126.74 million, slightly below the estimated $127.03 million, reflecting an 8.6% decline year-over-year [4] - Hospital segment net revenues reached $147.86 million, surpassing the average estimate of $147.41 million, with a year-over-year increase of 14.5% [4] - Blood Center segment net revenues were $56.01 million, exceeding the estimated $53.14 million, but showed a significant decline of 20.3% compared to the previous year [4] Stock Performance - Haemonetics shares have returned +14.8% over the past month, outperforming the Zacks S&P 500 composite's +13.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]